https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine
The Oxford-AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca , [33] [34] [35] using as a vector the modified chimpanzee adenovirus ChAdOx1

https://www.dw.com/en/what-you-need-to-know-about-astrazenecas-covid-19-vaccine/a-56537177
In a release on its website (March 25), AstraZeneca said the vaccine is 76% effective at preventing COVID-19 instead of an earlier figure of 79%. However, in the age group 65 and over the value is

https://www.nih.gov/news-events/news-releases/investigational-astrazeneca-vaccine-prevents-covid-19
AZD1222 demonstrated statistically significant vaccine efficacy of 78.9% in preventing symptomatic COVID-19 and 100% efficacy in preventing severe or critical disease and hospitalization. In participants 65 years and older, who comprised 20% of the trial population, vaccine efficacy against symptomatic COVID-19 was 79.9%.

https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html
The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose.. Results demonstrated vaccine efficacy of 76% (CI: 59% to 86%) after a first dose, with

https://www.cnbc.com/2021/03/25/astrazeneca-covid-vaccine-all-the-issues-and-problems-the-shot-has-faced.html
The problems for AstraZeneca got even worse in March, despite real-world data from the U.K. showing that the shot, alongside Pfizer's, was having indubitably positive effects with coronavirus

https://www.healthline.com/health/adult-vaccines/astrazeneca-vaccine
The AstraZeneca COVID-19 vaccine, now called Vaxzevria, is a viral vector vaccine, just like the Johnson & Johnson vaccine. It uses a chimpanzee adenovirus to carry spike proteins from the

https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals
Some countries in the European Union have temporarily suspended use of the AstraZeneca COVID-19 vaccine as a precautionary measure based on reports of rare blood coagulation disorders in persons who had received the vaccine. Other countries in the EU - having considered the same information - have decided to continue using the vaccine in their immunization programmes. Vaccination against

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32623-4/fulltext
2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials,1 with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their highest daily levels globally.2

https://www.npr.org/2021/03/22/979871536/astrazeneca-vaccine-is-effective-against-covid-19-phase-iii-study-says
AstraZeneca's vaccine can be stored, transported and handled at normal refrigerated conditions (2 to 8 degrees Celsius or 36 to 46 degrees Fahrenheit) for at least six months. The company said it

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704023/
Introduction. The ChAdOx1 nCoV-19 vaccine, commonly known as the Oxford-AstraZeneca vaccine, Covishield, or Vaxzevira, is one of four vaccines that received conditional approval for the prevention of COVID-19 in the UK (November 2021)1 2 The Oxford-AstraZeneca vaccine has been approved and licensed for use in over 170 countries, and approximately 1 billion doses have been administered

https://www.cnn.com/2021/03/22/health/astrazeneca-vaccine-efficacy-us-based-clinical-trial/index.html
AstraZeneca's Covid-19 vaccine showed 79% efficacy against symptomatic disease and 100% efficacy against severe disease and hospitalization in a new, US-based clinical trial, the company said

https://www.npr.org/2021/03/25/981088601/astrazenecas-latest-report-supports-effectiveness-of-covid-19-vaccine
AstraZeneca has updated the data about its COVID-19 vaccine after criticism that its previous statement was based on incomplete information. The update still finds that the shot is safe and effective.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277994/
The AstraZeneca vaccine, the world's most widely distributed COVID-19 vaccine as of April 2021 , has an overall positive benefit/risk ratio when considering the prevented cases of severe COVID-19, death, and likely long COVID-19 syndrome , and should play a key role in the fight of this pandemic in many settings. Funding

https://www.cnn.com/2021/03/19/health/astrazeneca-vaccine-us-questions/index.html
A nurse prepares a dose of the AstraZeneca/Oxford Covid-19 vaccine at the Edouard Herriot hospital on February 6, 2021 in Lyon, after the top French health authority on February 2, 2021 cleared

https://www.nytimes.com/2021/12/22/world/europe/turkey-issues-emergency-use-authorization-for-its-domestically-produced-vaccine.html
Turkey granted emergency-use approval for a domestically developed Covid vaccine on Wednesday, adding a third inoculation option for its citizens, as the Omicron variant increasingly fuels

https://www.nytimes.com/2020/11/24/health/astrazeneca-covid-vaccine.html
Andrew Testa for The New York Times. This month has seen a torrent of news about experimental vaccines to prevent Covid-19, with the latest development from AstraZeneca and the University of

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562017/
Methods: A prospective single-cohort study design was conducted to assess adverse events following immunization and associated factors of the first dose of Oxford/AstraZeneca's COVID-19 vaccine in Ayder Comprehensive specialized hospital. A structured questionnaire was administered consecutively to 423 participants. Follow-up data were collected 72 hours after vaccination via phone.

https://www.npr.org/sections/coronavirus-live-updates/2020/11/23/937881011/u-k-coronavirus-trial-promises-highly-effective-new-vaccine
Justin Tallis/AFP via Getty Images. U.K.-based pharmaceutical company AstraZeneca has developed a vaccine that initial results show to be "highly effective in preventing" COVID-19, the company

https://www.nytimes.com/2021/10/05/us/covid-astrazeneca-fda-antibody.html
AstraZeneca asks the F.D.A. to authorize an antibody treatment to prevent Covid-19. The company said the treatment cuts the risk of symptomatic Covid in people who have conditions that put them at

https://www.npr.org/sections/goatsandsoda/2021/06/01/1002067808/astrozenecas-rocky-rollout-the-woes-of-the-vaccine-of-the-world
On March 9, Nairobi, Kenya, began vaccinating groups, including health care workers and older people, with the AstraZeneca vaccine. From the get-go, the Oxford-AstraZeneca COVID-19 vaccine was

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965577/
Introduction. The latest pandemic caused by the novel SARS-CoV-2 virus has led to the emergence of coronavirus disease 2019 termed COVID-19. The disease first appeared in Wuhan, China in December 2019 as an outbreak of atypical pneumonia (Younis et al., 2020; Rana O; Zareef et al., 2020; Tsang et al., 2021; Younis et al., 2021).The virus has ever since spread at an unpreceded pace, exhausting

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585554/
Observational studies have demonstrated the potential efficacy of adjunctive therapy of low-dose aspirin (81-100 mg per day) in patients with COVID-19. In an earlier small observational cohort study of adult patients with COVID-19 by Chow et al., aspirin use ( n = 98) at least seven days before hospitalization or within 24 h of

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556685/
Results. Seven studies with a total of 34,415 patients were included in this systematic review and meta-analysis. The use of aspirin was associated with a reduced risk of mortality (RR 0.56, 95% CI 0.38-0.81, P = 0.002; I 2: 68%, P = 0.005). Sensitivity analysis by differentiating in-hospital (active aspirin prescription) and pre-hospital use